Clinical Scorecard: Addressing MASLD/MASH: Obstacles, Innovations, and the Future of Patient-Centric Approaches in Japan
At a Glance
Category
Detail
Condition
Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH)
Key Mechanisms
Metabolic dysfunction leading to liver steatosis, inflammation, fibrosis, and progression to cirrhosis and hepatocellular carcinoma
Target Population
Japanese adults, including lean and obese individuals, particularly those over 50 years old
Care Setting
Clinical hepatology and primary care settings in Japan with integration of non-invasive diagnostic tools
Key Highlights
MASLD prevalence in Japan is rising, reaching approximately 25.9% in individuals over 50 years, with lean MASLD comprising about 20.7% of cases.
Non-invasive liver disease assessment (NILDA), including vibration-controlled transient elastography (VCTE), is emerging as a key diagnostic tool, potentially replacing liver biopsy.
Emerging therapies such as lifestyle interventions, resmetirom, and semaglutide are reshaping management, but standardized guidelines and personalized treatment strategies remain needed.
Guideline-Based Recommendations
Diagnosis
Utilize non-invasive liver disease assessment (NILDA) techniques such as high-resolution imaging and blood-based biomarkers for early MASLD/MASH diagnosis.
Consider liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) as a surrogate endpoint for fibrosis evaluation.
Management
Implement lifestyle interventions focusing on diet and physical activity.
Consider pharmacologic treatments including resmetirom and semaglutide for MASH patients.
Adopt personalized treatment strategies accounting for patient heterogeneity and metabolic profiles.
Monitoring & Follow-up
Regularly monitor liver fibrosis progression using non-invasive methods.
Assess metabolic comorbidities such as diabetes, hypertension, and dyslipidemia during follow-up.
Risks
Recognize increased risk of cardiovascular disease and chronic kidney disease in MASLD patients.
Acknowledge higher morbidity and mortality risks in lean MASLD patients compared to non-lean counterparts.
Patient & Prescribing Data
Japanese adults with MASLD/MASH, including lean and obese subgroups
Emerging pharmacotherapies like resmetirom and semaglutide show promise; however, treatment must be individualized considering metabolic heterogeneity and comorbidities.
Clinical Best Practices
Incorporate non-invasive diagnostic tools early to identify MASLD/MASH and fibrosis stage.
Address metabolic risk factors comprehensively, including diabetes, hypertension, and dyslipidemia.
Tailor treatment plans to patient-specific factors such as BMI, metabolic status, and disease severity.
Increase clinician and public awareness of MASLD/MASH, especially in lean individuals who may be under-recognized.
Leverage Japan’s healthcare insurance and health checkup systems to facilitate early detection and management.
